Spectocor Mobile Cardiac Telemetry
Spectocor is a company formerly in the Mobile Cardiac Telemetry (MCT) space. The company was founded by 2 brothers with extensive background in the Cardiovascular market space. The core philosophy at Spectocor is to “continually improve our cardiac monitoring products and services in order to deliver a higher standard of analytics, quality assurance, and ultimately, a better patient experience and outcome”.
Competitive Advantage in Mobile Cardiac Telemetry
Spectocor has a unique competitive advantage. The company claims to have the only FDA approved device that combines Holter Monitoring, Cardiac Event Monitoring and Mobile Cardiac Telemetry. With this being their technological advantage, Spectocor can make a good story for streamlining all forms of cardiac monitoring all into one device. This can be a big advantage over the competition as most medical facilities are looking for ways to streamline their protocol for ordering the various forms of cardiac monitoring. In theory, if you can use only one device regardless of the study being ordered, you can offer great benefit to a medical facility rather than having a separate company and/or device for each type of study.
Superior Reporting Technology
Spectocor places great emphasis in marketing their products and services as being a clinically superior in reporting over other Mobile Cardiac Telemetry companies. The Spectocor report claims to have the sophistication of the most advanced Holter Monitoring reports. The Spectocor report includes classification and quantification of the following:
- Ventricular ectopic beats – PVC’s, Couplets, Bigenminy, Trigeminy, Triplets
- Supraventricular, Ectopics – Isolated PACs, SVT
- Atrial Fibrillation
- AF Burden
Company Accreditations
Spectocor is not currently active doing business. There is no longer information available in terms of manufacturing practices, legal notices and company accreditations other than the FDA approval on the PocketECG monitor imported from Poland.